Drug sensitivity analysis identified that the half maximal inhibitory concentration (IC50) of gemcitabine, pazopanib, sunitinib, and XL-184 in ccRCC patients with high HOTTIP expression was significantly higher than those in patients with low HOTTIP expression, indicating that patients with high HOTTIP expression were less sensitive to these treatments (Figure 6). Here, HOTTIP is linked to nonpapillary renal cell carcinoma.